Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 8/20 | 0.60 |
| ▸ | RAB9A | P51151 | 8/20 | 0.60 |
| ▸ | MAPT | P10636 | 8/20 | 0.60 |
| ▸ | MEN1 | O00255 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | ATM | Q13315 | 2/20 | 0.60 |
| ▸ | CASP3 | P42574 | 1/20 | 0.60 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.60 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.53 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | CASP1 | P29466 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30718798 | 1.00 | NPC1 (0.60) | NPC1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL6630673 | 0.85 | ALDH1A1 (0.53) | NPC1RAB9AMAPTMEN1KMT2A | |
| Trifluoromethanesulfonic Acid SCHEMBL15093758 | 0.84 | CYP3A4 (0.46) | NPC1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL7107657 | 0.81 | NPC1 (0.66) | NPC1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL4811418 | 0.81 | NPC1 (0.66) | NPC1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL29953906 | 0.81 | NPC1 (0.60) | NPC1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL28065831 | 0.81 | NPC1 (0.60) | NPC1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL496860 | 0.81 | NPC1 (0.60) | NPC1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL28837908 | 0.81 | NPC1 (0.60) | NPC1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL28864707 | 0.81 | NPC1 (0.60) | NPC1RAB9AMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2255877-B1 | Method for preparation of ruthenium-based metathesis catalysts with chelating alkylidene ligands | UMICORE AG & CO KG (DE) | 2014-09-24 | — | — | EP | claimed |
| EP-2029278-B1 | COMPLEX OF RUTHENIUM, METHOD OF PRODUCTION THEREOF AND USE THEREOF AS (PRE)CATALYST OF THE METATHESIS REACTION | UMICORE AG & CO KG (DE) | 2012-10-24 | — | — | EP | claimed |
| US-20250177965-A1 | HETEROGENEOUS CATALYSTS AND METHODS MAKING AND USING THEREOF | THE UNIVERSITY OF HONG KONG (CN) | 2025-06-05 | — | — | US | disclosed |
| CN-120054643-A | Heterogeneous catalysts and methods of making and using the same | 香港大学 | 2025-05-30 | — | — | CN | disclosed |
| US-20230144841-A1 | INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN | Praxis Biotech LLC (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230144841-A1 | INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN | Praxis Biotech LLC (US) | 2023-05-11 | — | — | US | disclosed |
| WO-2023072969-A1 | IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 | PERHA PHARMACEUTICALS (FR) | 2023-05-04 | — | — | WO | disclosed |
| EP-3381896-B1 | BIPHENYL COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2023-01-18 | — | — | EP | disclosed |
| US-20220396583-A1 | COMPOUNDS AS MODULATORS OF TLR2 SIGNALING | NEUROPORE THERAPIES, INC. (US) | 2022-12-15 | — | — | US | disclosed |
| US-20220396583-A1 | COMPOUNDS AS MODULATORS OF TLR2 SIGNALING | NEUROPORE THERAPIES, INC. (US) | 2022-12-15 | — | — | US | disclosed |
| US-11504364-B2 | Inhibitors of fibroblast activation protein | Praxis Biotech LLC (US) | 2022-11-22 | — | — | US | disclosed |
| EP-2019825-B1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BOEHRINGER INGELHEIM INT (DE) | 2010-09-01 | — | — | EP | disclosed |
| US-20090036481-A1 | Novel Azaindole Inhibitors of Mtp and Apob | MERCK PATENT GMBH (DE) | 2009-02-05 | — | — | US | disclosed |
| US-7470800-B2 | Titanium zeolite catalysts | LYONDELL CHEMICAL TECHNOLOGY, L.P. (US) | 2008-12-30 | — | — | US | disclosed |
| US-20070282116-A1 | Titanium zeolite catalysts | LYONDELL CHEMICAL TECHNOLOGY, L.P. | 2007-12-06 | — | — | US | disclosed |
| US-7276464-B2 | Titanium zeolite catalysts | LYONDELL CHEMICAL TECHNOLOGY, L.P. (US) | 2007-10-02 | — | — | US | disclosed |
| CN-1968749-A | Titanium zeolite catalysts | LYONDELL CHEMICAL TECH LP (US) | 2007-05-23 | — | — | CN | disclosed |
| EP-1773490-A1 | TITANIUM ZEOLITE CATALYSTS | Lyondell Chemical Technology, L.P. (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006007007-A1 | TITANIUM ZEOLITE CATALYSTS | LYONDELL CHEMICAL TECHNOLOGY, L.P. (US) | 2006-01-19 | — | — | WO | disclosed |
| US-20050283009-A1 | Titanium zeolite catalysts | LYONDELL CHEMICAL TECHNOLOGY, L.P. | 2005-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230144841-A1 | INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN | FAP, FIBP, FRS2 | NPC1 3869/4885RAB9A 2043/4885MAPT 3841/4885 |
| US-20090036481-A1 | Novel Azaindole Inhibitors of Mtp and Apob | APOB, MTPN, HDLBP | NPC1 46/4885RAB9A 4249/4885MAPT 3136/4885 |
| US-11504364-B2 | Inhibitors of fibroblast activation protein | FAP, FIBP, FRS2 | NPC1 3869/4885RAB9A 2043/4885MAPT 3841/4885 |
| US-20220396583-A1 | COMPOUNDS AS MODULATORS OF TLR2 SIGNALING | TLR2, TLR4, TLR3 | NPC1 684/4885RAB9A 3999/4885MAPT 237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.